Comparing the current results to its competitors, Aspira Women S Health Inc reported Revenue decrease in the 2 quarter 2026 year on year by -99.04 %, despite the revenue increase by the most of its competitors of 7.14 %, recorded in the same quarter.
Aspira Women s Health inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 68.42 %
Aspira Women S Health Inc 's Comment on Competition and Industry Peers
The company asserts that its Ova1 test has superior sensitivity compared to the Fujirebio Diagnostics test. Competitors developing ovarian cancer diagnostic assays include AOA Dx, ClearNote Health, Cleo Diagnostics, and Mercy BioAnalytics. Exact Sciences and Grail are working on multi-cancer early detection (MCED) tests that incorporate ovarian cancer detection. In the area of non-invasive diagnostic tools for endometriosis, competitors include Afynia, DotLab, Endodiag, HERA Biotech, Heranova, Proteomics International, and Ziwig. The company cites its experience in developing multi-omic clinical assays and a specialized women's health sales team as competitive strengths.
Myriad Genetics Inc's business model revolves around providing molecular diagnostic testing services and developing innovative precision medicine solutions that help identify and personalize treatment options for patients across various medical specialties.
Ncr Atleos Corporation operates on a business model focused on providing advanced technology solutions and services for various industries. They develop and deliver innovative digital products, payment solutions, and analytics tools to help businesses enhance their operations and improve customer experiences.
Natera Inc operates as a genetic testing company that provides non-invasive screening and diagnostic tests for reproductive health, oncology, and organ transplantation. The company's business model is built around offering cost-effective and accurate genetic testing solutions for both patients and healthcare providers. Natera primarily generates revenue by selling its proprietary tests and associated analysis services to customers, including hospitals, laboratories, and physicians.
Sources:
Aspira Women s Health inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Aspira Women s Health inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
